Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies

A method of determining the efficacy of therapy in the treatment of amyloidosis, comprising:

• (A) administering to a patient in need thereof an effective amount of a compound selected from the group consisting of structures 1, 3-5, 8-16, 18, and 20-45, wherein at least one substituent moiety in the compound comprises a detectable label selected from the group consisting of 3H, 131I, 125I, 123I, 76Br, 75Br, 18F, 19F, TTC, 13C, and 14C:
• (B) imaging said patient;
• then
• (C) administering to said patient in need thereof at least one anti-amyloid agent;
• (D) subsequently administering to said patient in need thereof an effective amount of a compound selected from the group consisting of structures 1, 3-5, 8-16, 18, and 20-45, wherein at least one substituent moiety in the compound comprises a detectable label selected from the group consisting of 3H, 131I, 125I, 123I, 76Br, 75Br, 18F, 19F, 11C, 13C, and 14C;
• (E imaging said patient;
• and
• (F) comparing levels of amyloid deposition in said patient before treatment with said at least one anti-amyloid agent to levels of amyloid deposition in said patient after treatment with said at least one anti-amyloid agent.